Health Care·Biotechnology·$5.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.64 | N/A | +15.90% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.64 | N/A | +15.90% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management conveyed a cautious outlook, focusing on long-term goals while addressing immediate challenges. They did not provide specific guidance for the upcoming quarters.
Management emphasized the importance of ongoing research and development efforts.
They acknowledged the challenges faced in the current market environment.
Xenon Pharmaceutical reported a loss per share that was better than expected, but the lack of revenue figures and guidance contributed to a negative stock reaction. The stock fell 1.34% as investors digested the cautious tone from management regarding future prospects. Without clear guidance, uncertainty remains about the company's short-term performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WORKDAY INC A
Feb 26, 2024